每经AI快讯，1月30日，赛诺医疗(688108.SH)公告称，预计2025年归属于上市公司股东的净利润为4300 万元至5000万元，较上年同期增加4150万元至4850万元，同比增长2767%至3233%。业绩增长主要因冠 脉及神经介入业务收入增长、营业成本和管理费用小幅增长、销售费用及研发费用下降、资产减值损失 大幅减少，叠加上年同期净利润基数较小。 ...

赛诺医疗公告称，2025年预计营收5.19亿元至5.26亿元，同比增长13%至15%；预计归属于上市公司股 东的净利润4300万元至5000万元，同比增长2767%至3233%；扣非净利润3000万元至3580万元，实现扭 亏为盈。营收增长主因冠脉介入业务和神经介入业务收入增加；净利润大幅增长受营收增长、成本费用 变动及上年基数小等因素影响。 ...

格隆汇1月30日｜赛诺医疗公告称，预计2025年归属于上市公司股东的净利润为4300万元至5000万元， 较上年同期增加4150万元至4850万元，同比增长2767%至3233%。主要因冠脉及神经介入业务收入增 长、营业成本和管理费用小幅增长、销售费用及研发费用下降、资产减值损失大幅减少，叠加上年同期 净利润基数较小。 ...

赛诺医疗第三届董事会第十次会议审议通过公司向上海浦东发展银行股份有限公司天津分行申请不超过 人民币2亿元的综合授信额度，其中0.5亿元为信用方式，1.5亿元由控股子公司赛诺神畅医疗科技有限公 司提供连带责任保证担保。授信期限一年，用于公司日常经营流动资金。董事会授权公司管理层办理相 关手续，决议有效期2年。 赛诺医疗于2026年1月20日召开董事会，审议通过向上海浦东发展银行股份有限公司天津分行申请不超 过人民币2亿元的综合授信额度，授信期限一年。其中0.5亿元为信用方式，1.5亿元由公司控股子公司赛 诺神畅医疗科技有限公司提供连带责任保证担保。该担保为无偿提供，不收取担保费用，公司不提供反 担保。董事会授权管理层在授信额度内办理相关手续，该事项在董事会审议通过后2年内无需再提交审 议。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自公司公告汇总：赛诺医疗完成1,904,000股限制性股票归属，上市流通日期为2026年1月22日。 来自公司公告汇总：赛诺医疗获董事会批准向浦发银行申请2亿元综合授信额度，期限一年。 来自公司公告 ...

Core Insights - The coronary access devices are essential consumables for percutaneous coronary intervention (PCI) surgeries, directly impacting surgical outcomes and complication control [1][6] - The industry is supported by a series of policies in China, including centralized procurement, innovation approvals, and grassroots medical construction, laying a solid foundation for high-quality development [6][10] - The number of coronary artery disease patients is steadily increasing globally and in China, with projections indicating 220 million patients worldwide and 27.879 million in China by 2024, highlighting significant growth potential for the industry [10] Industry Overview - Coronary access devices are specialized medical equipment and consumables used in PCI surgeries to establish and maintain access from the body surface to the coronary arteries, ensuring the smooth execution of angiography, balloon dilation, and stent implantation [1][6] - The devices are categorized into four main types: puncture devices, catheter systems, sheath sets, and auxiliary devices for pressure monitoring and vascular closure [3][4] Development Background - The development of coronary access devices is crucial for reducing cardiovascular disease mortality, enhancing medical accessibility, and promoting high-end device localization [6][8] - Recent policies in China aim to improve centralized procurement mechanisms, accelerate innovation device approvals, and standardize medical insurance payments, providing guidance for industry development [6][10] Market Analysis - The global coronary balloon dilatation catheter market is expanding, with functional balloons growing at a faster rate; the market size is expected to increase from $560 million in 2020 to $960 million in 2024, with a compound annual growth rate (CAGR) of 8.49% [12][14] - In China, the market is characterized by structural adjustments and rapid growth, with the general balloon market experiencing a temporary decline due to centralized procurement but expected to rebound, while functional balloons are projected to grow significantly, with a CAGR of 19.28% from 2024 to 2028 [14][16] Competitive Landscape - The competitive landscape of the coronary access device industry is tiered, with foreign companies dominating the high-end market while domestic leaders are accelerating their market penetration; by 2024, domestic companies are expected to capture 54.9% of the coronary balloon market [14][15] Future Trends - The industry is expected to evolve along three main directions: technological upgrades, deepening domestic substitution, and expansion of grassroots markets [16] - Innovations such as biodegradable materials and smart functions will drive high-end product iterations, while local companies will enhance core component localization through material and manufacturing process advancements [17][18] - The promotion of tiered diagnosis and treatment will reshape market demand, with a growing need for cost-effective and standardized products suitable for grassroots settings [18]

证券之星消息，截至2026年1月21日收盘，赛诺医疗(688108)报收于24.0元，上涨4.94%，换手率 6.67%，成交量27.75万手，成交额6.63亿元。 1月21日的资金流向数据方面，主力资金净流入6917.57万元，占总成交额10.43%，游资资金净流出 2441.95万元，占总成交额3.68%，散户资金净流出4475.62万元，占总成交额6.75%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-21 | 24.00 4.94% | | 6917.57万 | 10.43% | -2441.95万 | -3.68% | -4475.62万 | -6.75% | | 2026-01-20 | 22.87 | 0.70% | -3121.66万 | -7.82% | -581.86万 | -1.46% | 3703.52万 | 9.28% | | 2026-01-19 ...

Summary of Key Points Core Viewpoint - On January 22, a total of 8 companies had their restricted shares unlocked, with a total unlock volume of 300 million shares, amounting to a market value of 9.725 billion yuan based on the latest closing price [1]. Group 1: Unlock Volume and Market Value - The companies with the highest unlock volumes are ChaoYan Co., Ltd. (1.50 billion shares), XingFu Electronics (1.09 billion shares), and TaiKaiYing (15.28 million shares) [1]. - In terms of unlock market value, XingFu Electronics (5.308 billion yuan), ChaoYan Co., Ltd. (3.582 billion yuan), and ZhongTung High-Tech (345 million yuan) lead the list [1]. Group 2: Unlock Ratio - The companies with the highest unlock ratios relative to their total share capital are ChaoYan Co., Ltd. (35.05%), XingFu Electronics (30.38%), and TaiKaiYing (6.90%) [1].

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Group 1 - The core point of the news is that Sino Medical (688108) has completed the second vesting of its 2022 restricted stock incentive plan, with 1,904,000 shares set to be listed on January 22, 2026, increasing the total share capital from 416,048,000 to 417,952,000 shares [1][3] - On January 20, 2026, Sino Medical's stock closed at 22.87 yuan, up 0.7%, with a turnover rate of 4.23%, a trading volume of 175,800 shares, and a transaction amount of 399 million yuan [1] - The company’s board approved an application for a comprehensive credit limit of up to 200 million yuan from Shanghai Pudong Development Bank Tianjin Branch, with a one-year term, where 50 million yuan is credit-based and 150 million yuan is guaranteed by its subsidiary [2][3] Group 2 - On January 20, 2026, the net outflow of main funds was 31.22 million yuan, while retail investors saw a net inflow of 37.04 million yuan [3] - The company’s board has authorized management to handle the relevant procedures for the credit limit application, which does not require further board approval within two years [2][3]

（记者 曾健辉） 每日经济新闻 每经AI快讯，赛诺医疗1月20日晚间发布公告称，公司第三届第十次董事会会议于2026年1月20日在北 京市海淀区高梁桥斜街59号中坤大厦7层公司会议室召开。会议审议了《关于向上海浦东发展银行股份 有限公司天津分行申请授信额度并接受子公司担保的议案》等文件。 每经头条（nbdtoutiao）——"一周干完一年的活"，一款AI编程工具让硅谷程序员集体"上瘾"！科技公 司CEO：一辈子钻研的技能被它一次性解决，让人兴奋又恐惧 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...